GSK’s DoJ Settlement Requires Execs To Forfeit Bonuses If Misconduct Occurs

GlaxoSmithKline pleads guilty to promoting Paxil and Wellbutrin off-label and failing to report Avandia safety data to FDA; civil portion of settlement resolves off-label and kickback allegations involving nine products. New corporate integrity agreement gives OIG authority to require a recall.

More from Legal & IP

More from Pink Sheet